

References — MAbCampath

1. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. *Blood* 2002 May 15;99(10):3554-61.
2. Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. *J Clin Oncol* 1997 Apr;15(4):1567-74.
3. McCune J, Gockerman J, Moore J, et al. Alemtuzumab in relapse or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. *Leukemia Lymphoma* 2002;43(5):1007-11.
4. Rai, KR, Coutre S, Rizzieri, et al. Efficacy and safety of alemtuzumab (Campath-1h) in refractory B-CLL patients treated on a compassionate basis (Abstract). *Blood* 2001; 98(11);365a.
5. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, Mollgard L, Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). *Blood* 2002 Aug 1;100(3):768-73.
6. Kennedy B, Rawstron A, Carter C, Ryan M, Speed K, Lucas G, Hillmen P. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. *Blood* 2002 Mar 15;99(6):2245-7.
7. O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S, Keating M. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. *J Clin Oncol* 2001 Mar 1;19(5):1414-20.
8. Cancer Care Ontario website <http://www.cancercare.on.ca/>
9. BC Cancer Agency website <http://www.bccancer.bc.ca/>
10. Pho K (ed.). *Kingston Cancer Care Handbook*, 7th ed. The Kingston Regional Cancer Center 2002; Kingston.
11. *Acronyms in Cancer Chemotherapy*, 7th ed. Lilly Oncology 1999, Toronto.